S-1: A new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer

Clinical Lung Cancer

Volumn 10, Issue 4, 2009, Pages 290-294

  Okamoto, Isamu ^a   Fukuoka, Masahiro ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 Fluorouracil; CDHP; Combination chemotherapy; Potassium oxonate; Prodrug; Tegafur

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROPYRIMIDINE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; NAVELBINE; OXONIC ACID; PACLITAXEL;

ADVANCED CANCER; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE DRUG DOSE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

EID: 70349446637     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2009.n.040     Document Type: Review

References (41)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57 : 43-66.
2. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997; 15 : 2996-3018.
3. Socinski MA, Crowell R, Hensing TE, et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:277S-89S.
4. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26 : 3552-9.
5. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311 : 899-909.
6. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346 : 92-8.
7. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007; 18 : 317-23.
8. Shirasaka T, Nakano K, Takechi T, et al. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996; 56 : 2602-6.
9. Takechi T, Nakano K, Uchida J, et al. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 1997; 39 : 205-11.
10. Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer 1993; 71 : 493-509.
11. Kato T, Shimamoto Y, Uchida J, et al. Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil. Anticancer Res 2001; 21 : 1705-12.
12. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993; 53 : 4004-9.
13. Boku N, Yamamoto S, Shirao K, et al. Randomized Phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). J Clin Oncol 2007; 25(18 suppl):200s (Abstract LBA4513).
14. Kawahara M, Furuse K, Segawa Y, et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 2001; 85 : 939-43.
15. Nokihara H, Nagai S, Kato T, et al. Phase II study of S-1 in non-small cell lung cancer (NSCLC) patients previously treated with a platinum-based regimen. J Thorac Oncol 2007; 2(suppl 4):S687.
16. Ichinose Y, Yoshimori K, Sakai H, et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 2004; 10 : 7860-4.
17. Endo M, Yamamoto N, Sakai H, et al. Phase II study of 3-weekly S-1 plus cisplatin in patients with advanced non-small cell lung cancer. Ann Oncol 2006; 17(suppl 9):Abstract 752.
18. Kaira K, Sunaga N, Yanagitani N, et al. A phase I dose-escalation study of S-1 plus carboplatin in patients with advanced non-small-cell lung cancer. Anticancer Drugs 2007; 18 : 471-6.
19. Tamura K, Okamoto I, Ozaki T, et al. Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. Eur J Cancer 2009; [Epub ahead of print].
20. D'Addario G, Pintilie M, Leighl NB, et al. Platinum-based versus non-platinumbased chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005; 23 : 2926-36.
21. Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992; 10 : 16-20.
22. Negoro S, Masuda N, Takada Y, et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 2003; 88 : 335-41.
23. Vanhoefer U, Harstrick A, Achterrath W, et al. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001; 19 : 1501-18.
24. Houghton JA, Cheshire PJ, Hallman JD II, et al. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. Clin Cancer Res 1996; 2 : 107-18.
25. Takiuchi H, Narahara H, Tsujinaka T, et al. Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002). Jpn J Clin Oncol 2005; 35 : 520-5.
26. Yamada Y, Yasui H, Goto A, et al. Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer. Int J Clin Oncol 2003; 8 : 374-80.
27. Goto A, Yamada Y, Yasui H, et al. Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol 2006; 17 : 968-73.
28. Okamoto I, Nishimura T, Miyazaki M, et al. Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: West Japan Thoracic Oncology Group 3505. Clin Cancer Res 2008; 14 : 5250-4.
29. Satouchi M, Kotani Y, Katakami N, et al. Randomized phase II study of two different schedules of gemcitabine and oral TS-1 in chemo-naïve patients with advanced non-small cell lung cancer. J Clin Oncol 2008; 26(15 suppl):449s (Abstract 8103).
30. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). [corrected] J Clin Oncol 2003; 21 : 2237-46.
31. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353 : 123-32.
32. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366 : 1527-37.
33. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350 : 2129-39.
34. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304 : 1497-500.
35. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101 : 13306-11.
36. Okabe T, Okamoto I, Tsukioka S, et al. Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. Mol Cancer Ther 2008; 7 : 599-606.
37. Johnston PG, Drake JC, Trepel J, et al. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 1992; 52 : 4306-12.
38. Copur S, Aiba K, Drake JC, et al. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 1995; 49 : 1419-26.
39. Ohyanagi F, Yamamoto N, Horiike A, et al. A phase II study of cisplatin, S-1 and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. J Clin Oncol 2008; 26(15 suppl):410s (Abstract 7556).
40. Ichikawa W, Takahashi T, Suto K, et al. Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 2004; 91 : 1245-50.
41. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006; 107 : 1589-96.